Business · 21/04/2003Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for EXELON Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for EXELON's patent extension application, which seeks to prolong the patent protection for a human drug product, as required by law.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →